Page 83 - GTM-2-4

Global Translational Medicine Prognosis of relapse in squamous cell lung cancer

percentage of lymphocytes with the CXCR2 receptor, and 3.9 months after surgery, whereas in those with a normal
the percentage of monocytes with the CD44v6 receptor post-operative level, relapses occurred later, after
in the total population of these blood cells, as well as 8.5 months (Figure 1A). Examining the level of CXCR2
the results of the calculated combined model, decreased (% in lymphocytes) 3 weeks after resection as a prognostic
to values below the threshold values (TV) (TV: SCC = criterion revealed that exceeding the TV at this time
1.51 ng/ml; CXCR2 [% in lymphocytes] = 10.7%; CD44v6 was also diagnosed in a patient who developed a relapse
[% in monocytes] = 2.20%; combined model=0.213 ). The after 3.9 months (Figure 1B). However, in the patient
[6]
most pronounced decrease was observed for the combined experiencing a relapse 8.3 months after surgery, the level
model (39.1%), while for individual indicators, their TVs of the indicator 3 weeks postoperatively was below the
did not exceed 32.0%. In this group, relapse developed in TV, classifying them into a low-risk group for relapse.
only three cases during the 1-year observation period. Stratifying patients into high- and low-risk groups based
In the remaining 15 of the 57 patients examined, the on CD44v6 (% in monocytes) 3 weeks after surgery
levels of the studied indicators 3 weeks after surgical showed a patient from the low-risk group developing
treatment also decreased but remained above TVs. a relapse after 6.3 months. In contrast, a patient with a
For these patients, the initial median drop at 3-week relapse after 3.9 months exhibited an increased level
postoperatively for the individual outcome ranged from of the indicator, along with SCC antigen and CXCR2
36.9% to 45.1%, and for the combined model outcome, it (% in lymphocytes) (Figure 1C). The combined model,
was 48.9%. Tumor recurrence occurred within a year in incorporating all three aforementioned indicators,
nine out of these 15 patients, as diagnosed based on CT demonstrated superior predictive ability. For a patient
results (Table 2). with a relapse diagnosed after 3.9 months, the calculation

The first relapses in the group of patients with an result exceeded TV 3 weeks after surgery. The first relapse
elevated post-operative SCC antigen level were diagnosed in patients with a value below the threshold 3 weeks after

Table 2. Changes in the concentration of SCC antigen, the percentage of lymphocytes with the CXCR2 receptor, and monocytes
with the CD44v6 receptor in the populations of these blood cells in patients who developed relapse (12 out of all 57 patients)

Patient Index Before treatment After tumor resection Time to relapse (months)
3 weeks 3 months 6 months
1 SCC antigen (ng/ml) 2.47 1.55 1.73 2.12 3.9
CXCR2 (% in lymphocytes) 19.30 10.80 13.40 17.65
CD44v6 (% in monocytes) 4.20 2.56 2.93 3.51
Combined model 0.503 0.257 0.341 0.467
2 SCC antigen (ng/ml) 2.71 1.73 1.90 2.21 4.3
CXCR2 (% in lymphocytes) 17.15 10.25 13.00 17.10
CD44v6 (% in monocytes) 2.15 2.20 2.55 3.10
Combined model 0.434 0.231 0.313 0.421
3 SCC antigen (ng/ml) 3.75 2.89 3.05 3.36 5.6
CXCR2 (% in lymphocytes) 20.90 10.90 13.65 17.80
CD44v6 (% in monocytes) 4.85 3.85 4.20 4.75
Combined model 0.598 0.273 0.355 0.466
4 SCC antigen (ng/ml) 1.93 1.56 1.73 2.04 6.3
CXCR2 (% in lymphocytes) 17.4 13.30 16.15 20.40
CD44v6 (% in monocytes) 3.85 2.10 2.55 3.30
Combined model 0.429 0.22 0.307 0.422
5 SCC antigen (ng/ml) 2.02 1.61 1.79 2.12 7.2
CXCR2 (% in lymphocytes) 18.1 14.2 17.1 21.3
CD44v6 (% in monocytes) 3.90 2.40 2.80 3.45
Combined model 0.501 0.227 0.313 0.434
(Cont’d...)

Volume 2 Issue 4 (2023) 4 https://doi.org/10.36922/gtm.2209